Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2011-07-05 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
关于股东持股变动的公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a change in shareholding by a significant shareholder (武汉国有资产经营公司) and its related party. It details the sale of shares and the resulting shareholding percentage. There is no financial report, earnings data, or management discussion. The content fits the definition of a Major Shareholding Notification, which reports changes in significant share ownership levels crossing thresholds.
2011-07-05 Chinese
关于“马应龙眼药制作技艺”入选国家非物质文化遗产名录的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the inclusion of a company's traditional medicine technique into the national intangible cultural heritage list. It is a formal public notice by the company's board but does not contain financial data, regulatory filings, or report information. It is not related to financial performance, management changes, voting results, or any other specific financial filing category. Given its nature as a public announcement without financial or regulatory content, it best fits into the Regulatory Filings (RNS) category as a general regulatory announcement.
2011-06-11 Chinese
2010年度利润分配及公积金转增股本实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an announcement regarding the implementation of the 2010 annual profit distribution and capital reserve conversion to share capital by Ma Yinglong Pharmaceutical Group. It details the dividend distribution, share bonus, tax information, important dates such as the record date, ex-dividend date, and dividend payment date, and changes in share capital. The document is an official announcement of the dividend and capital increase plan approved at the 2010 annual shareholders meeting. It does not contain comprehensive financial statements or detailed financial performance data, but rather focuses on the dividend and share capital distribution details. The document length is 3236 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of Notice of Dividend Amount (DIV).
2011-05-16 Chinese
关于2011年度审计机构名称变更、办公地址迁移的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the change of the audit firm's name and office address. It does not contain any financial statements, audit opinions, or detailed audit information. It is an official notification about administrative changes related to the audit firm, not a full audit report or annual report. The document length is only 356 characters, indicating it is a brief announcement rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2011-04-30 Chinese
第七届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed at a board meeting of the company 马应龙药业集团股份有限公司. It details the date, attendance, and voting results of the board meeting, specifically the approval of the 'Board Secretary Work Rules'. There is no financial data, no mention of annual or quarterly reports, no audit information, no shareholder voting results, and no other report publication. The content is focused on board/management decisions and internal governance matters. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA. Confidence is high due to clear keywords and context.
2011-04-30 Chinese
2010年度股东大会的法律意见书
AGM Information Classification · 90% confidence The document is a legal opinion letter from a law firm regarding the legality and procedures of the 2010 Annual General Meeting (AGM) of the company. It discusses the convening, attendance, voting procedures, and resolutions passed at the AGM. The document does not contain the actual AGM materials or presentations but serves as a legal validation of the AGM process. Therefore, it is related to the AGM but is not the AGM materials themselves. Given the content and purpose, this document fits best under AGM Information (AGM-R), which includes presentations and materials shared during the AGM or related official documents about the AGM process.
2011-04-30 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.